Mr. Chair, I'll answer the question in a couple of parts.
One is that there shouldn't be any concern about supply itself. We do know that there are supplies of AstraZeneca vaccine should the second dose be AstraZeneca.
The more important point is the answer to the last part of the question, which is that I think the international data is looking quite promising towards the effectiveness and safety of a mixed schedule—an mRNA vaccine, for example, following the AstraZeneca vaccine. I am optimistic that there's in fact an option there. Again, we await the NACI examination of that data as per the timeline Dr. Tunis mentioned.
I just want to acknowledge that it is, of course, anxiety provoking, and that's understandable. For those who received that first dose, that answer will be available within a reasonable timeframe for that second dose.